Search - tctmd.com

Displaying 101 - 112 of 112

Sort: Relevancy | Date

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Jason Kahn

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Presenter: Antonio Colombo

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Video

» Interview

ACC 2022: The FAME 3 Trial - Quality of Life After Fractional Flow Reserve-guided Stenting Compared with Coronary Bypass Surgery

April 3, 2022

Video

» Interview

ACC 2019: STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation

March 18, 2019

Advertisement

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

ACC 2022: The FAME 3 Trial - Quality of Life After Fractional Flow Reserve-guided Stenting Compared with Coronary Bypass Surgery

ACC 2019: STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content